SECONDMENT AGREEMENTSecondment Agreement • August 30th, 2024 • I-Mab • Pharmaceutical preparations • Maryland
THIS SECONDMENT AGREEMENT (the “Agreement”) is made effective as of August 28, 2024 (the “Effective Date”) by and between I-MAB Biopharma US Limited, a Maryland corporation, with a principal place of business at 2440 Research Blvd, Suite 400, Rockville, MD 20850, USA (“I-Mab US”) and ABio-X Holdings, Inc., a Delaware corporation, with a principal place of business at 117 Kendrick Street, Suite 400, Waltham, MA 02494, USA (“ABio-X”). I-Mab US and ABio-X (each a “Party”, collectively, the “Parties”) hereby agree to the terms set forth below.
